Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06077942
Other study ID # FXShoulder2022-01
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 6, 2022
Est. completion date December 30, 2032

Study information

Verified date October 2023
Source FX Shoulder Solutions
Contact Ted McKittrick, BA
Phone 7242493364
Email tmckittrick@fxshouldersolutions.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Subjects implanted with the shoulder replacement medical devices manufactured by FX Shoulder Solutions and distributed by FX Shoulder Solutions.


Description:

To evaluate patient outcomes following shoulder replacement with FX Shoulder Solutions medical devices To demonstrate effectiveness, safety and survivorship of FX Shoulder Solutions medical devices To provide data and analysis to FX Shoulder Solutions to meet regulatory requirements. To provide data and analysis for presentations, abstracts, publications and other public release of results. Clinical data in the Investigator's clinic notes and patient files regarding demographics, baseline medical and shoulder status, surgical procedure and implant components, and any completed postoperative clinical data will be collected retrospectively as data for the Study following signed patient consent and enrollment into the study. Each patient will be evaluated prospectively, and clinical data collected at the first baseline clinical evaluation using the protocol specified evaluations following study enrollment with successive postoperative evaluations in accordance with the postoperative intervals.


Recruitment information / eligibility

Status Recruiting
Enrollment 600
Est. completion date December 30, 2032
Est. primary completion date December 30, 2032
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Received an FX Shoulder Solutions replacement medical device in accordance with the Indications for Use based upon surgeons' determination and standard of care for the selected device system beginning January 1, 2018, through June 30, 2023. Exclusion Criteria: - Patient who does not meet the inclusion criteria above

Study Design


Related Conditions & MeSH terms


Intervention

Device:
FX Artificial Shoulder Prosthesis
Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System, Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135

Locations

Country Name City State
United States OrthoArizona Gilbert Arizona
United States Advanced Orthopedics Institute The Villages Florida

Sponsors (1)

Lead Sponsor Collaborator
FX Shoulder Solutions

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Primary Effectiveness Endpoint The primary safety endpoint is the occurrence of any serious, device-related adverse event through 24 months of follow-up defined as an onset date before or on 730 days following the index surgery. For the primary endpoint, device-related will be defined as definite, probable, or possible relationship to the device. 24 months
Primary Number of participants who are at a minimum of 2 years postoperative follow-up based upon the following composite clinical success (CCS) of the Patient Reported Outcome Surveys and Investigator Range of Motion (ROM) assessments. Adjusted Constant Score > 70
No continuous radiolucency or device migration/subsidence
No revision surgery or removal
No serious device related adverse event
The Study will continue to follow patients prospectively to 10 years postoperative to track survivorship.
10 years
Secondary Adjusted Constant Score The Constant-Murley score (CMS) is a validated 100-points scale composed of a number of individual parameters. These parameters define the level of pain and the ability to carry out the normal daily activities of the patient. The test is divided into four subscales: pain (15 points), activities of daily living (20 points), strength (25 points) and range of motion (40 points) with the subject completing the assessment prior to the Investigator completing their part of the assessment. The higher the score, the higher the quality of the function.
An Adjusted Constant score will be calculated using normalized values to account for age and gender, as based upon anatomical gender at birth.
3, 6, 12, 24 months, 5 and 10 years.
Secondary QuickDASH QuickDASH measures an individual's ability to complete tasks, absorb forces, and severity of symptoms. The QuickDASH tool uses a 5-point Likert scale from which the patient can select an appropriate number corresponding to his/her severity level/ function level. The higher the score, the higher the function and lower pain in the patient. 3, 6, 12, 24 months, 5 and 10 years.
Secondary American Shoulder and Elbow Surgeon (ASES) ASES is a validated patient-reported outcome which is composed of 10 functional questions and one pain VAS. The total score is of 100 maximum points and weighted evenly between pain and function 3, 6, 12, 24 months, 5 and 10 years.
Secondary Visual Analog Scale (VAS). A validated measurement of pain in a patient where 0 indicates no pain and 100 indicates severe pain. The VAS is a straight horizontal line of fixed length. A validated measurement of pain in a patient where 0 indicates no pain and 100 indicates severe pain. The VAS is a straight horizontal line of fixed length. 3, 6, 12, 24 months, 5 and 10 years
Secondary Range of Motion ROM - The patient performs active movements in all functional planes for the shoulder.
Includes flexion, extension, abduction, adduction and internal and external rotation. Investigator estimates the range of movement and compares the affected with the unaffected shoulder and the normal expected range.
3, 6, 12, 24 months, 5 and 10 years.
Secondary Number of Participants Who Have a Secondary Surgical Intervention (SSI) SSI's are re-operations, revisions, and removals. 24 months and at 5 and 10 years
Secondary Device Related Adverse Events. An adverse event that is related to the use of a device. 24 months and at 5 and 10 years postoperative
Secondary Serious Adverse Event Led to a death,
Resulted in life threatening illness or injury*
Resulted in patient hospitalization or prolongation of existing hospitalization,
Resulted in patient disability or permanent damage or required intervention to prevent permanent impairment/damage
Led to a congenital abnormality or birth defect
24 months and at 5 and 10 years postoperative
Secondary Serious Adverse Device Effects (SADE) Adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event. 24 months and at 5 and 10 years postoperative.
Secondary Number of Participants with Radiographic Reviews and Assessments. Monitor implant integrity and signs of implant loosening 24 months, at 5 years and 10 years postoperative
See also
  Status Clinical Trial Phase
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Not yet recruiting NCT04448106 - Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis Phase 2
Not yet recruiting NCT06032416 - DenCT Shoulder Bone Quality Evaluation N/A
Enrolling by invitation NCT05067543 - Perform Humeral System Study
Completed NCT04641546 - Effectiveness of Occupation-Based Intervention Compared With Therapeutic Exercise for Older Adults With Shoulder OA. N/A
Recruiting NCT05868148 - Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study
Completed NCT03431857 - Multi Centre Study on TESS V2 Shoulder System
Recruiting NCT05861960 - Endogenous Pain Modulation Study
Recruiting NCT06078865 - FX Shoulder Prospective Clinical Study
Recruiting NCT04929951 - The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis Phase 1
Recruiting NCT04968405 - Catalyst CSR Shoulder System for Semi or Total Shoulder Arthroplasty N/A
Enrolling by invitation NCT05500066 - AEQUALIS™ FLEX REVIVE™ Study (REVIVE)
Active, not recruiting NCT05002959 - TESS V3 Modular Total Shoulder System PMCF
Active, not recruiting NCT06171542 - Efficacy of a Single Image Guided Injection of CTM for Glenohumeral Arthritis Phase 1
Recruiting NCT05487274 - TSA v RSA in Osteoarthritic Shoulders With Greater Than 15 Degrees of Retroversion N/A